:::

詳目顯示

回上一頁
題名:兒童風濕疾病及其醫療利用與罹癌風險之探討
書刊名:臺灣公共衛生雜誌
作者:馬震中 引用關係蘇有村林佟威鄭怡婷
作者(外文):Ma, Chen-chungSu, Yu-tsunLin, Tung-weiCheng, I-ting
出版日期:2017
卷期:36:4
頁次:頁386-396
主題關鍵詞:兒童風濕疾病癌症醫療利用ChildrenPediatric rheumatic diseaseCancerMedical utilization
原始連結:連回原系統網址new window
相關次數:
  • 被引用次數被引用次數:期刊(0) 博士論文(0) 專書(0) 專書論文(0)
  • 排除自我引用排除自我引用:0
  • 共同引用共同引用:0
  • 點閱點閱:99
目標:風濕疾病為一種慢性的炎症,可能會增加罹癌風險,因此本研究目的在探討台灣地區兒童風濕病人罹癌之風險及其罹癌前醫療利用之情形。 方法:本研究採回溯性研究設計,運用次級資料分析,資料來源為全民健保資料庫,選取2000年至2012年診斷為風濕疾病之兒童,以紅斑性狼瘡及幼年特發性關節炎等八種風濕疾病進行觀察;使用Cox models分析罹癌症風險,並以Mann-Whitney U Test檢定病人罹癌前醫療利用之變化。 結果:整體兒童風濕病人相較於兒童非風濕病人高出3.71倍罹癌風險,其中紅斑性狼瘡、幼年特發性關節炎與修格連氏症候群的罹癌風險分別為3.94倍、5.93倍與5.29倍;藥物中,曾使用免疫調節劑者罹癌風險約增加5.65倍,曾使用生物製劑罹癌風險高出約26.01倍;另外,兒童風濕病人在罹癌前的醫療利用變化呈現門診利用增加、住院利用減少,經Mann-Whitney U Test檢定均未達顯著差異。 結論:綜合研究結果,兒童罹患風濕疾病會增加其罹癌風險,因此本研究建議衛生主管機關應加強重視兒童風濕病人的醫療照護,避免將來支出更多的社會成本。
OBJECTIVES: A clinical manifestation of rheumatic disease is chronic inflammation that may increase the risk of cancer. The purpose of this study was to explore the risk of cancer and the precancerous medical utilization by children with rheumatism in Taiwan. METHODS: This was a retrospective study with secondary data analysis. The data were drawn from the National Health Insurance Research Database from 2000 to 2012. Patients under the age of 18 with a diagnosis of pediatric rheumatic disease, including systemic lupus erythematosus, juvenile idiopathic arthritis, Sjögren’s syndrome, scleroderma, polymyositis, dermatomyositis, vasculitis and Behçet’s disease. A total of 1,741 cases were identified. The Cox proportional hazards model was used to analyze the risk of cancer, and the Mann-Whitney U Test was used to assess whether the patient’s medical use was different from that in the year prior to the diagnosis of cancer. RESULTS: The overall risk for children with rheumatism compared with non-rheumatic patients was 3.71 times the risk for cancer; for systemic lupus erythematosus, juvenile idiopathic arthritis and Sjögren’s syndrome, the cancer risk was 3.94 times, 5.93 times and 5.29 times, respectively. The risk for cancer was increased by 5.65 times in those who had used immunoregulatory drugs, and this was 26.01 times more than that of those who had used biological agents. For children with rheumatism, in the year before the diagnosis of cancer and in terms of overall medical use before cancer, the number of outpatient visits and expenses increased, but the number of hospitalizations, hospital days, and cost reduction were not significantly different. CONCLUSIONS: Based on the results of this study, we suggest that the health authorities pay more attention to the medical care of children with rheumatism in order to avoid future social costs.
期刊論文
1.Coussens, L. M.、Werb, Z.(2002)。Inflammation and cancer。Nature,420(6917),860-867。  new window
2.See, L. C.、Kuo, C. F.、Chou, I. J.、Chiou, M. J.、Yu, K. H.(2013)。Sex-and age-specific incidence of autoimmune rheumatic diseases in the Chinese population: a Taiwan population-based study。Semin Arthritis Rheum,43,381-386。  new window
3.Mantovan, A.、Allavena, P.、Sica, A.、Balkwill, F.(2008)。Cancer-related inflammation。Nature,454,436-444。  new window
4.Diak, P.、Siegel, J.、La, Grenade L.、Choi, L.、Lemery, S.、McMahon, A.(2010)。Tumor necrosis factor a blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration。Arthritis Rheum,62,2517-2524。  new window
5.蔡維河、侯素秋、黎家銘、楊清泉(20110800)。臺灣阿茲海默症病人確診前的門診醫療利用。臺灣公共衛生雜誌,30(4),316-325。new window  延伸查詢new window
6.Lai, N. S.、Tsai, T. Y.、Li, C. Y.、Koo, M.、Yu, C. L.、Lu, M. C.(2014)。Increased frequency and costs of ambulatory medical care utilization prior to the diagnosis of rheumatoid arthritis: a national population-based study。Arthritis Care Res (Hoboken),66,371-378。  new window
7.Liang, J. A.、Sun, L. M.、Yeh, J. J.(2012)。Malignancies associated with systemic lupus erythematosus in Taiwan: a nationwide population-based cohort study。Rheumatol Int,32,773-778。  new window
8.Kok, V. C.、Horng, J. T.、Huang, J. L.(2014)。Population-based cohort study on the risk of malignancy in East Asian children with juvenile idiopathic arthritis。BMC Cancer,14,634。  new window
9.白其卉(2010)。打一場公平的拳賽--淺談選樣時的可比性。台灣腦中風學會會,17,10-11。  延伸查詢new window
10.蔡永富、周貝倫、張麟生(20070800)。修格連氏症候群。基層醫學,22(8),264-269。  延伸查詢new window
11.Yu, K. H.、Kuo, C. F.、Huang, L. H.、Huang, W. K.、See, L. C.(2016)。Cancer risk in patients with inflammatory systemic autoimmune rheumatic diseases: a nationwide population-based dynamic cohort study in Taiwan。Medicine (Baltimore),95,e3540。  new window
12.Trinchieri, G.(2012)。Cancer and inflammation: an old intuition with rapidly evolving new concepts。Annu Rev Immunol,30,677-706。  new window
13.Bernatsky, S.、Ramsey-Goldman, R.、Clarke, A.(2006)。Malignancy and autoimmunity。Curr Opin Rheumatol,18,129-134。  new window
14.Beukelman, T.、Haynes, K.、Curtis, J. R.(2012)。Rates of malignancy associated with juvenile idiopathic arthritis and its treatment。Arthritis Rheum,64,1263-1271。  new window
15.Liang, Y.、Yang, Z.、Qin, B.、Zhong, R.(2014)。Primary Sjogren's syndrome and malignancy risk: a systematic review and meta-analysis。Ann Rheum Dis,73,1151-1156。  new window
16.Ruperto, N.、Martini, A.(2014)。Juvenile idiopathic arthritis and malignancy。Rheumatology (Oxford),53,968-974。  new window
17.Zhang, J. Q.、Wan, Y. N.、Peng, W. J.(2013)。The risk of cancer development in systemic sclerosis: a meta-analysis。Cancer Epidemiol,37,523-527。  new window
18.Katz, J. N.、Barrett, J.、Liang, M. H.、Kaplan, H.、Roberts, W. N.、Baron, J. A.(1998)。Utilization of rheumatology physician services by the elderly。Am J Med,105,312-318。  new window
19.Yabroff, K. R.、Lamont, E. B.、Mariotto, A.、Warren, J. L.、Topor, M.、Meekins, A.、Brown, M. L.(2008)。Cost of care for elderly cancer patients in the United States。JNCI: Journal of the National Cancer Institute,100(9),630-641。  new window
20.Andersen, Ronald M.(1995)。Revisiting the behavioral model and access to medical care: Does it matter?。Journal of Health and Social Behavior,36(1),1-10。  new window
學位論文
1.周光宇(2013)。探討幼年皮肌炎的發生率與共病風險- 台灣人口調查研究(碩士論文)。國立中央大學。  延伸查詢new window
圖書
1.兒童過敏氣喘免疫及風濕病醫學會(2015)。兒童特發性關節炎--2015年治療建議。台北:兒童過敏氣喘免疫及風濕病醫學會。  延伸查詢new window
其他
1.鄧正梁。病從何入?從「免疫」談起...獨一無二的紅斑性狼瘡!,http://blog.xuite.net/liang310/LE/8330878。  延伸查詢new window
2.中華民國兒童癌症基金會。兒童惡性淋巴瘤,http://www.ccfroc.org.tw/child/child_affection_read.php?ajd=13。  延伸查詢new window
3.財團法人風濕病基金會。淋巴球與免疫病,http://www.arthritisfound.org.tw/doctor-acticle/%E6%B7%8B%E5%B7%B4%E7%90%83%H8%88%87%E5%85%8D%E7%96%AB%E7%97%85/。  new window
4.Food and Drug Administration。Early communication about an ongoing safety review of Tumor Necrosis Factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, and Cimzia),http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetylnformationforPatientsandProviders/DrugSafetylnformationforHeathcareProfessionals/ucm070725.htm。  new window
5.台灣兒科醫學會。轉知「行政院衛生署」來函,http://www.pediatr.org.tw/news/news_info.asp?id=12。  延伸查詢new window
6.衛生福利部中央健保署。健保用藥品項查詢,http://www.nhi.gov.tw/query/query1.aspx?menu=21&menu_id=713&webdata_id=3510&WD_ID=851。  延伸查詢new window
7.衛生福利部中央健保署。治療「類風濕性關節炎」生物製劑之健保給付現況,http://www.nhi.gov.tw/information/NewsDetail.aspx?No=1003&menu=9&menu_id=544。  延伸查詢new window
 
 
 
 
第一頁 上一頁 下一頁 最後一頁 top
:::
無相關博士論文
 
無相關書籍
 
無相關著作
 
QR Code
QRCODE